Theravance Biopharma (NASDAQ:TBPH) Releases Quarterly Earnings Results, Misses Estimates By $0.13 EPS

Theravance Biopharma (NASDAQ:TBPH) announced its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.10) EPS for the quarter, missing the consensus estimate of $0.03 by ($0.13), FiscalAI reports. The firm had revenue of $17.70 million for the quarter, compared to the consensus estimate of $17.78 million. Theravance Biopharma had a net margin of 104.34% and a return on equity of 19.58%.

Theravance Biopharma Stock Performance

TBPH stock traded down $0.01 during trading on Friday, hitting $17.01. 237,595 shares of the company traded hands, compared to its average volume of 351,599. The firm has a market capitalization of $876.19 million, a PE ratio of 7.73 and a beta of 0.19. Theravance Biopharma has a 1 year low of $8.33 and a 1 year high of $21.03. The company has a 50-day moving average of $15.79 and a 200-day moving average of $17.37.

Analysts Set New Price Targets

Several equities analysts have recently commented on the company. HC Wainwright increased their price objective on Theravance Biopharma from $20.00 to $27.00 and gave the company a “buy” rating in a research report on Monday, March 2nd. B. Riley Financial increased their price objective on Theravance Biopharma from $14.00 to $17.00 and gave the company a “neutral” rating in a research report on Tuesday, April 7th. Weiss Ratings lowered Theravance Biopharma from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Friday, April 10th. Oppenheimer lowered Theravance Biopharma from an “outperform” rating to a “market perform” rating in a research report on Thursday, March 5th. Finally, Zacks Research upgraded Theravance Biopharma from a “hold” rating to a “strong-buy” rating in a report on Thursday, March 19th. Two equities research analysts have rated the stock with a Strong Buy rating, two have given a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $21.83.

Insiders Place Their Bets

In related news, SVP Rhonda Farnum sold 31,067 shares of the stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $13.96, for a total transaction of $433,695.32. Following the completion of the sale, the senior vice president directly owned 232,699 shares in the company, valued at $3,248,478.04. This represents a 11.78% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. 6.90% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Theravance Biopharma

Several institutional investors have recently bought and sold shares of TBPH. Arrowstreet Capital Limited Partnership purchased a new stake in Theravance Biopharma in the 3rd quarter worth approximately $10,611,000. Janus Henderson Group PLC lifted its holdings in Theravance Biopharma by 214.8% in the 4th quarter. Janus Henderson Group PLC now owns 400,496 shares of the biopharmaceutical company’s stock worth $7,493,000 after buying an additional 273,288 shares during the period. Two Sigma Investments LP lifted its holdings in Theravance Biopharma by 1,199.9% in the 3rd quarter. Two Sigma Investments LP now owns 231,272 shares of the biopharmaceutical company’s stock worth $3,377,000 after buying an additional 213,480 shares during the period. HRT Financial LP lifted its holdings in Theravance Biopharma by 892.8% in the 4th quarter. HRT Financial LP now owns 232,852 shares of the biopharmaceutical company’s stock worth $4,356,000 after buying an additional 209,397 shares during the period. Finally, Rock Springs Capital Management LP purchased a new stake in Theravance Biopharma in the 4th quarter worth approximately $3,906,000. 99.10% of the stock is currently owned by hedge funds and other institutional investors.

About Theravance Biopharma

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.